Beyond ‘May Contain’: Solving the Over-Labelling Crisis in eCommerce Food Safety
20 December 2025
Marketplace-First Brands: How Fulfillment Strategy Impacts Seller Ratings and Buy Box Wins
20 December 2025
OUR GOAL
To provide an A-to-Z e-commerce logistics solution that would complete Amazon fulfillment network in the European Union.
In functional mushrooms, most compliance conversations start with a comforting question: Is the species legal? Lion’s Mane. Reishi. Chaga. Everyone relaxes. The SKU goes live. The marketing team warms up the “ancient wisdom” angle.
And then a regulator asks a different question. A sharper one.
What exactly is this ingredient—fruiting body, mycelium, or an extract? And what did you do to it?
That’s where the trap snaps shut. Because in the EU and UK, “traditional” is not a vibe. It’s a legal status built on history of consumption and the nature of the production process. A product can be “fine” in its raw form and still end up unauthorised when the finished ingredient no longer resembles what regulators recognise as historically consumed.
This article is a deep dive for manufacturers and retailers who want to keep selling across the EU/UK without waking up to delistings, seized consignments, or the slow-motion disaster of “relabel everything” emails. It is not legal advice. It is the operational reality behind modern enforcement.
The Compliance Divide: Fruiting Body vs. Mycelium
This is where most brands accidentally generalise. They treat “mushroom” like one ingredient class, when regulators often treat it like several different product identities. Same species. Different material. Different process. Different risk profile.
If you want to stay sellable across multiple markets, you need to get specific early—before procurement and branding lock you into a format you can’t defend.
Why fruiting bodies usually feel “safe”—and why that comfort can be misleading
Fruiting bodies are the visible mushroom. The part historically eaten, brewed, or cooked. That history matters because Novel Food status is anchored to what was consumed to a significant degree prior to the key regulatory cut-off date.
This is why many businesses treat fruiting-body powders as the “default safe lane.” And in many cases, authorities do accept that lane—especially when the ingredient is plainly a dried, milled fruiting body with no aggressive standardisation and no exotic processing narrative attached.
But “usually safe” is not “automatically safe.” The moment you move from “mushroom” to “engineered ingredient,” you can drift into Novel Food territory fast. Not because the species changed. Because the product did.
Mycelium is not the mushroom consumers think they bought
Mycelium is the vegetative root-like network. In supplements, it’s frequently grown on a substrate (often grain), harvested as biomass, then dried and milled. That manufacturing reality creates two compliance issues.
First, the history of consumption argument becomes harder. Authorities may accept a fruiting body’s traditional use while still questioning whether mycelium-derived products—especially modern biomass formats—have meaningful pre-1997 consumption in the same way.
Second, the product identity blurs. Is it “mycelium”? Is it “myceliated grain”? Is it a mix? That ambiguity is a labelling risk and an enforcement magnet, because it makes it harder to prove what the consumer is actually ingesting.
The uncomfortable truth: fungi is a regulated lane, and process is the lever
Novel Food rules explicitly capture categories that include fungi-derived foods and ingredients. That doesn’t mean “all mushrooms are novel.” It means that once you’re operating in fungi-based formats—mycelium, extracts, isolates—the burden of clarity rises.
When your product is mycelium-based, you’re often trying to sell “tradition” through a form that looks industrial: fermentation tanks, biomass, standardised actives. This is exactly where authorities ask whether you still qualify for the comfort blanket of historic consumption.
Strategic Insight: If your compliance file answers only “what species is it?” you don’t have a compliance file. You have a product description.
The “Molecular Change” Trigger
Here’s the part that catches experienced operators off-guard. Even when the raw material is familiar, the finished ingredient can be treated as unfamiliar if your processing changes what the food is in a meaningful way. Regulators don’t only look at your Latin name—they look at structure, composition, and the method that produced it.
That’s why extraction and standardisation aren’t just technical choices. They’re classification choices.
Novel Food isn’t only about new species—it’s about new structures and new processes
Many brands underestimate the second trapdoor: Novel Food status can be triggered by a new or intentionally modified molecular structure, or by a production process not used prior to the cut-off date that results in significant changes in composition or structure.
This is why “high potency” is not just a marketing claim. It’s a regulatory signal.
When you take a traditional mushroom and push it through modern extraction, fractionation, enzymatic treatment, or fermentation-driven modification, you may create something authorities no longer recognise as “the food that has history.” You’ve shifted the product from mushroom to ingredient technology.
Extraction methods that raise questions faster than the species does
Not every extraction triggers Novel Food classification. But some methods are more likely to invite a “significant change” discussion, especially when paired with standardised high-actives positioning.
High-scrutiny processing themes tend to include supercritical CO₂ extraction, ultrasonic-assisted extraction, submerged fermentation/biomass production, and aggressive standardisation into concentrated fractions. The more you emphasise “molecular precision,” the more you invite molecular scrutiny.
The compliance question is simple: are you still selling a traditional food, or have you manufactured a new one?
Why your documentation must describe the process like an engineer, not a marketer
Regulators don’t evaluate a vibe. They evaluate a dossier.
If your spec sheet says “dual extract,” but your manufacturing flowchart shows multiple solvents, temperature ramps, enzymatic steps, membrane filtration, and post-extraction standardisation, the gap between narrative and reality becomes the risk. If your label says “mushroom extract,” but your technical file effectively describes “isolated fraction,” you are advertising novelty without meaning to.
Pro Tip: Treat “standardised to X%” as a compliance event, not a marketing line. The higher the standardisation, the stronger your burden to explain what changed—and why the end product still fits its claimed regulatory category.
High-Risk Species Spotlight
Compliance risk is rarely distributed evenly across the category. Some species attract scrutiny because they’re popular, poorly understood by consumers, or inconsistently treated across markets. Others become “high-risk” simply because enforcement has already created a paper trail.
If you manufacture or retail across multiple EU Member States (or into the UK), assume that what is tolerated quietly in one market can still be challenged loudly in another.
Turkey Tail: a live example of how fast “traditional” can become “unauthorised”
Turkey Tail (Trametes versicolor) has become a case study because it’s widely discussed in wellness circles and increasingly visible in supplements. And it’s also showing up in enforcement signals.
In late 2025, an EU RASFF notification flagged Turkey Tail (Trametes versicolor) in a food supplement as an unauthorised novel food. For operators, that’s not abstract. It’s a practical warning that the ingredient is in a higher-scrutiny zone and that documentation, positioning, and market selection matter more than usual.
Cordyceps: inconsistent market assumptions meet regulatory friction
Cordyceps adds another layer of complexity because “Cordyceps” often functions as a category word in marketing, while enforcement tends to land at species and production-method level.
RASFF notifications have flagged Cordyceps sinensis as an unauthorised novel food in supplements. That matters even if your supplier insists their material is “traditional,” because enforcement arrives through border checks, competitor complaints, and marketplace audits.
Cordyceps is also where fermentation/mycelium narratives are common. The more your ingredient is produced through controlled cultivation and processed into concentrated formats, the more you should expect questions about Novel Food authorisation status.
The Member State reality: “non-binding” tools and divergent enforcement
Operators love a definitive list. The EU reality is messier.
The European Commission’s Novel Food status catalogue is explicitly described as non-binding and based on information provided by Member States. That means it can guide you, but it doesn’t guarantee uniform enforcement. When status is unclear, competent authority consultation exists for a reason: borderline cases are common, and interpretations can vary.
This creates a commercial hazard: one market feels permissive, another market feels strict, and your cross-border operation sits in the middle holding the risk. The safest posture is designed for the strictest plausible interpretation—not the friendliest anecdote.
The “On-Hold” Claim Limbo
Claims are where good products become bad files. Functional mushrooms rarely sell on taste; they sell on outcomes. But outcomes are exactly where food law gets sharp, especially when the language drifts toward medical territory.
The trap here is that brands can be “ingredient-compliant” and still become enforcement targets through the way they present the product to consumers.
Botanical health claims are a minefield—because “on-hold” isn’t “approved”
The EU’s health claims framework is structured, and many botanical-related claims sit in a long-running limbo. “On-hold” does not mean “authorised.” It often means “not concluded,” with transitional and national nuances that can shift how claims are tolerated in practice.
For mushroom brands, that means the same claim set can be perceived differently depending on market, language, and context. It’s not just what you say. It’s what the claim implies, and whether the overall presentation stays in the “food supplement” lane.
“Medicinal by presentation”: when your label turns your supplement into a medicine
In the UK, claims to treat, prevent, or cure disease with foods and food supplements are prohibited, and “borderline” assessment exists because presentation can pull a product into medicines regulation.
Mushroom brands get burned not because they say “supports wellbeing,” but because they drift into disease language, and aggressive testimonial framing that reads like a medical promise. Once you’re there, you’re no longer debating Novel Food status. You’re debating classification risk, enforcement, delistings, and ad platform bans.
The operational consequence: claims chaos creates supply chain chaos
Claims errors feel like a marketing issue—until they become a logistics event.
If a marketplace suspends a listing, inventory gets stranded. If an authority challenges label wording, you may face relabelling, quarantines, or withdrawals. If a product is treated as unauthorised, cross-border shipments can get blocked, and returns become non-resellable waste.
This is why regulatory discipline belongs inside your operational workflows: controlled label versions, market-specific SKUs, traceable batches, and the ability to place stock on QA hold instantly when a risk signal appears.
Strategic Insight: The fastest way to destroy margin in regulated supplements isn’t a high CAC month. It’s a compliance-triggered stop-sale with pallets already paid for and nowhere to go.
The Manufacturer-Retailer Playbook for Staying Sellable
Most compliance failures aren’t caused by one dramatic mistake. They’re caused by missing structure. A supplier says “it’s fine,” a brand believes them, a retailer copies the listing, and suddenly the entire chain is exposed when a question arrives.
The fix is boring. It’s also profitable: build a repeatable system that makes your products defensible across markets, channels, and audit styles.
Build a “status file” that answers the real question: what is the food, exactly?
For mushroom products, a credible status file typically includes identity, form, process, compositional impact, and consumption history. Keep it practical. Not 200 pages of marketing.
The essentials:
ingredient identity (species, part used: fruiting body vs mycelium)
manufacturing description (process steps, solvents, fermentation parameters where relevant)
specifications (markers, contaminants, allergens, substrate residues)
evidence of history of consumption where relied on
documented positions or consultations where relevant (especially for borderline formats)
If your file cannot explain the delta between “traditional mushroom” and “your ingredient,” assume your risk is higher than you think.
Design your commercial strategy around “available-to-promise compliance”
Retailers and DTC brands obsess over ATP for inventory. You need ATP for compliance. That means being able to answer, in real time: which batches are sellable in which markets, under which labels, with which claim sets. If you cannot segment that operationally, you are one enforcement signal away from pulling everything, everywhere.
This is where mature warehousing matters: lot/batch traceability, controlled co-packing, market-specific pick/pack rules, and the ability to quarantine inventory instantly while you adjust labels or channel strategy.
Treat reverse logistics as contamination control, not “returns processing”
In supplements, returns are rarely simple. A returned unit is typically not resellable. It’s a quality and compliance liability.
Your reverse logistics workflow should protect the rest of your inventory: quarantine zones, batch-based reconciliation, disposal controls, and clean reporting. If you ever face a stop-sale or withdrawal scenario, the difference between “we can isolate affected batches” and “we have to freeze the whole SKU line” is the difference between a manageable incident and a cash-flow crisis.
Compliance-Ready Fulfillment for High-Scrutiny Products
Functional mushroom brands don’t lose money only on regulation. They lose money on operational inability to respond when regulation moves.
FLEX. Fulfillment supports manufacturers and retailers with the warehouse mechanics that keep regulated SKUs sellable:
batch and LPN tracking, rapid QA holds, controlled relabelling and kitting, and market-specific pick/pack rules that prevent the wrong label landing in the wrong country.
When your products sit in the regulatory spotlight, execution becomes part of compliance—and the fastest wins come from building a supply chain that can adapt without panic.
